Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer

Breast Cancer

Volumn 21, Issue 6, 2014, Pages 780-785

  Neugut, Alfred I ^a,b,c,i   Hillyer, Grace Clarke ^c   Kushi, Lawrence H ^d   Lamerato, Lois ^e   Leoce, Nicole ^c   Ambrosone, Christine B ^f   Bovbjerg, Dana H ^g   Mandelblatt, Jeanne S ^h   Hershman, Dawn L ^a,b,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Kaiser Permanente of Northern California ^*  (United States)

^c Henry Ford Health System ^*  (United States)

^d KAISER PERMANENTE   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ NewYork Presbyterian Hospital   (United States)

Author keywords

Adherence; Adjuvant therapy; Breast cancer; Early discontinuation; Non initiation; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST NEOPLASMS; COHORT ANALYSIS; FEMALE; HUMAN; MEDICATION COMPLIANCE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84939882871     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-014-0543-1     Document Type: Article

References (26)

1. Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:121–36.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.
3. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–20.
4. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.
5. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29–36.
6. Pivot X, Romieu G, Bonnefoi H, et al. PHARE trial results comparing 6–12 months of trastuzumab in adjuvant early breast cancer. Ann Oncol. (in press).
7. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.
8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.
9. Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann VR, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol. 2005;23:6639–46.
10. Bickell NA, McEvoy MD. Physicians’ reasons for failing to deliver effective breast cancer care: a framework for underuse. Med Care. 2003;41:442–6.
11. Silliman RA, Guadagnoli E, Weitberg AB, Mor V. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol. 1989;44:M46–50.
12. Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat. 2006;99:313–21.
13. Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys. 2006;65:1353–60.
14. Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Nathanson SD, Ambrosone CB, et al. The breast cancer quality of care study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy. Breast J. 2012;18:203–13.
15. Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD, et al. Non-initiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study. J Clin Oncol. 2012;30:3800–9.
16. Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD, et al. Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat. 2012;134:419–28.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
18. Coulson SG, Kumar VS, Manifold IM, Hatton MQ, Ramakrishnan S, Dunn KS, et al. Review of testing and use of adjuvant trastuzumab across a cancer network–are we treating the right patients? Clin Oncol (R Coll Radiol). 2010;22:289–93.
19. Barron JJ, Cziraky MJ, Weisman T, Hicks DG. HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist. 2009;14:760–8.
20. Montserrat M, Leveque D, Barthelemy P, Bergerat JP. Duration of adjuvant trastuzumab treatment in routine practice. Anticancer Res. 2012;32:4585–8.
21. Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014;32:927–34.
22. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24:2750–6.
23. Hershman DL, Buono D, McBride RB, Tsai WY, Neugut AI. Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. Cancer. 2009;115:3848–57.
24. Balasubramanian BA, Gandhi SK, Demissie K, August DA, Kohler B, Osinubi OY, et al. Use of adjuvant systemic therapy for early breast cancer among women 65 years of age and older. Cancer Control. 2007;14:63–8.
25. Bhargava A, Du XL. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer. 2009;115:2999–3008.
26. Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the cancer and leukemia group B experience. J Clin Oncol. 2007;25:3699–704.